Reclast/Aclasta, approved for five indications, g
ained additional US approval in May as the only therapy to prevent postmenopausal osteoporos
is with convenient, less-frequent dosing, while Europe
an approval was granted in June for treatment of osteoporosi
s caused by steroid treatment in men an ...[+++]d postmenopausal women, an indication already approved in the US.